



March 25, 2025

To whom it may concern

Company Name: Nihon Parkerizing Co., Ltd.
Representative: Masayuki Aoyama
Representative Director, President and Executive Officer
(Code: 4095 TSE Prime)
Inquiries: Toshiyuki Aishima, Executive Officer and
General Manager, Corporate Division
(Phone. 03-3278-4333)

**Notice on Establishment of Subsidiary through Company Split
(Simplified Incorporation-type Company Split)**

Nihon Parkerizing Co., Ltd. (hereinafter the "Company") hereby announces that it has resolved at its Board of Directors meeting held today, effective July 1, 2025 (scheduled), to transfer the rights and obligations relating to the Company's medical device business to Parker MedTech Corporation (the "New Company"), which will be newly established through an incorporation-type company split (the "Incorporation-type Company Split"). (the "New Company") through an incorporation-type company split (the "Company Split"), as described below.

Since this is a simplified incorporation-type company split in which the Company is the sole Company, some disclosure items and contents are omitted from this announcement.

1. Purpose of the Company Split

Based on the management philosophy of "creating new value for resources through surface modification of all kinds of materials for the effective use of the earth's limited resources and contributing to the preservation of the global environment and the creation of a prosperous society," our group is making a broad contribution to the realization of a sustainable society by utilizing a variety of surface modification technologies.

Under such circumstances, since 2018, we have been engaged in the medical device business using surface modification technology (the "Business") with the mission of "realizing the well-being of patients and everyone concerned worldwide by providing medical devices that use our surface modification technology" further to reduce the burden on both patients and doctors. We develop and provide highly functional products that reduce the burden on both patients and doctors.

The purpose of this corporate separation is to promote the execution of agile and flexible business strategies and to secure and develop specialized human resources for the diversification of products handled as we aim for further development and growth of the medical device business.

2. **Summary of the Incorporation-type Company Split**

(1) Schedule of the Company Split

Date of Board of Directors' resolution approving the new Company Split plan: March 25, 2025

Scheduled date of corporate separation (effective date): July 1, 2025 (planned)

*As this is a simplified incorporation-type company split as stipulated in Article 805 of the Companies Act, the Company will carry out the Company Split without obtaining approval at a general meeting of shareholders.

(2) Method of the Company Split

The Company Split is a simplified company split in which the Company is the splitting Company, and the Company to be newly established is the successor company. The newly established Company will be a wholly owned subsidiary of the Company.

(3) Allocation of shares upon Company Split

The newly established Company will issue 200 shares of common stock upon Company Split, and all the shares will be allocated to the Company.

(4) Treatment of stock acquisition rights or bonds with stock acquisition rights upon Company Split

There is no applicable treatment.

(5) Increase or decrease in capital as a result of Company Split

There will be no increase or decrease in the Company's capital as a result of the Company Split.

(6) Rights and obligations to be succeeded by the newly established Company

The assets, liabilities, contracts and other rights and obligations related to the business will be succeeded in accordance with the provisions of the incorporation-type Company Split plan dated March 25, 2025.

(7) The prospect of fulfilling financial obligations

The amount of assets of the newly established Company after the effective date of the Company Split is expected to exceed its liabilities. Furthermore, no events are currently foreseen after the effective date of the Company Split that would hinder the performance of obligations to be incurred by the newly established Company. Based on the above, we have determined that the newly established Company is expected to be able to fulfill its obligations after the effective date of the Company Split.

3. Outline of the Parties Involved in Company Split

	Split Company (As of March 31, 2024)	Newly established Company (Scheduled for July 1, 2025)
Company name	Nihon Parkerizing Co.	Parker MedTech Corporation
Location of head office	16-8 Nihonbashi 2-chome, Chuo-ku, Tokyo	10-5 Nihonbashi 3-chome, Chuo-ku, Tokyo
Name of representative	Masayuki Aoyama, President and Executive Officer	Kuniyoshi Murakami, President and Representative Director
Business	Chemicals, toll processing, and engineering businesses	Manufacture and sale of medical devices
Capital	4,560 million yen	10 million yen
Date of establishment	July 12, 1928	July 1, 2025 (scheduled)
Number of shares issued	132,604,524 shares	200 shares (planned)
Accounting period	March 31	March 31
Major shareholders and shareholding ratio	The Master Trust Bank of Japan (Trust Account) 10.25% Nippon Life Insurance 5.92% NORTHERN TRUST CO. (AVFC) RE FIDELITY FUNDS 5.72% Meiji Yasuda Life Insurance 4.23% The Chiba Bank, Ltd. 4.02%	Nihon Parkerizing Co. 100%

4. Consolidated financial position and operating results of the splitting Company for the latest fiscal year ending March 31, 2024

Net assets	219,885 million yen
Total assets	269,819 million yen
Shareholders' equity per share	1,623.03 yen
Net sales	125,085 million yen
Operating income	15,258 million yen
Ordinary income	19,945 million yen
Net income	13,194 million yen
Net income per share	114.43 yen

5. **Overview of the business to be split**

(1) Business to be split

Medical equipment business (manufacture and sale of medical equipment)

(2) Operating results of the business to be split (for the fiscal year ending March 31, 2024)

Net sales 58 million yen

(3) Items and amounts of assets and liabilities to be split (as of March 31, 2024)

Assets		Liabilities	
Item	Book value	Item	Book value
Current assets	43 million yen	Current liabilities	-
Fixed assets	125 million yen	Fixed liabilities	-
Total amount	168 million yen	Total amount	-

(Note) The actual amounts of assets and liabilities to be split will be determined after adding or subtracting any increase or decrease up to the effective date of the Company Split to the above amounts.

6. **Status of the Company after the Company Split**

There will be no change in the Company name, address, name and title of representative, business activities, capital stock, or fiscal year after the Company Split.

7. **Future Outlook**

The impact of this Company Split on the Company's consolidated financial results is expected to be minor. However, the Company will promptly announce if any matters requiring disclosure occur in the future.

-End-